Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 0.79 |
| ▸ | PPARA | Q07869 | 19/20 | 0.79 |
| ▸ | PPARD | Q03181 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4455878 | 0.94 | PPARG (0.76) | PPARGPPARAPPARD | |
| SCHEMBL4452141 | 0.92 | PPARG (0.66) | PPARGPPARAPPARD | |
| SCHEMBL30515117 | 0.88 | PPARG (1.00) | PPARGPPARA | |
| SCHEMBL18095621 | 0.88 | PPARG (1.00) | PPARGPPARA | |
| SCHEMBL4680474 | 0.88 | PPARG (1.00) | PPARGPPARA | |
| SCHEMBL1400636 | 0.87 | PPARD (1.00) | PPARAPPARD | |
| SCHEMBL4683362 | 0.86 | PPARG (0.86) | PPARGPPARA | |
| SCHEMBL4678920 | 0.86 | PPARA (1.00) | PPARGPPARA | |
| SCHEMBL820903 | 0.86 | PPARA (1.00) | PPARGPPARA | |
| SCHEMBL30515161 | 0.86 | PPARA (1.00) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130195798-A1 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | THE CHANCELLORS, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2013-08-01 | — | — | US | disclosed |
| EP-2054076-A2 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | United Therapeutics Corporation (US) | 2009-05-06 | — | — | EP | disclosed |
| US-7476742-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476742-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476742-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-01-13 | — | — | US | disclosed |
| US-20080131398-A1 | Glucosidase inhibitors; interferons; antifibrotics; hepatitis | UNITED THERAPEUTICS CORPORATION | 2008-06-05 | — | — | US | disclosed |
| WO-2008063727-A2 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | UNITED THERAPEUTICS CORPORATION (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20050107392-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107392-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents | GPR119, INSR, IRS1 | PPARG 280/4885PPARA 156/4885PPARD 467/4885 |
| US-20080131398-A1 | Glucosidase inhibitors; interferons; antifibrotics; hepatitis | GBA3, EIF2AK2, GAA | PPARG 710/4885PPARA 955/4885PPARD 983/4885 |
| US-20130195798-A1 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | EIF2AK2, ZC3HAV1, HAVCR2 | PPARG 2565/4885PPARA 2017/4885PPARD 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.